NASDAQ:AMGNAmgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMGN stock has increased by 25.4% and is now trading at $249.04. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Amgen.

Amgen will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Thursday, April, 30th. The medical research company reported $4.17 EPS for the quarter, beating analysts' consensus estimates of $3.70 by $0.47. The medical research company had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The company's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.56 EPS. View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, March 4th. Shareholders of record on Monday, May 18th will be paid a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Friday, May 15th. View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Thursday, April, 30th. The company provided EPS guidance of $14.85-15.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.34. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.21 billion.

28 brokers have issued 1-year price objectives for Amgen's shares. Their forecasts range from $185.00 to $291.00. On average, they expect Amgen's stock price to reach $246.08 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View analysts' price targets for Amgen.

News stories about AMGN stock have trended somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Amgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.09%), Cullinan Associates Inc. (0.03%), Wedge Capital Management L L P NC (0.02%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.02%) and Cardinal Capital Management Inc. (0.01%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Manning & Napier Group LLC, Thomasville National Bank, Municipal Employees Retirement System of Michigan, Gradient Investments LLC, West Branch Capital LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, and OmniStar Financial Group Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Cullinan Associates Inc., O Keefe Stevens Advisory Inc., DNB Asset Management AS, State of Alaska Department of Revenue, Renaissance Investment Group LLC, Canandaigua National Corp, and Exane Derivatives. View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $249.04.

Amgen has a market capitalization of $146.50 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]